A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo, according to a new study. Continue Reading at Science Daily
- Here is What We Know About the Rollout of the Johnson & Johnson Vaccine.
- Zoom sees more growth after ‘unprecedented’ 2020